Literature DB >> 7595098

Expression of mouse alpha-macroglobulins, lipoprotein receptor-related protein, LDL receptor, apolipoprotein E, and lipoprotein lipase in pregnancy.

L Overbergh1, K Lorent, S Torrekens, F Van Leuven, H Van den Berghe.   

Abstract

The expression of the proteinase inhibitors of the alpha-macroglobulin family and of their clearance receptor was analyzed in the mouse during pregnancy, embryonal development, and adolescence. In total we studied seven partners of a complicated network of interactions in proteolysis and lipid metabolism:alpha-2-macroglobulin, murinoglobulin, the alpha-2-macroglobulin receptor/lipoprotein receptor related protein, the murine equivalent of the receptor associated protein or the 44 kDa heparin binding protein, the low density lipoprotein receptor, apolipoprotein E, and lipoprotein lipase. The data demonstrate that: i) the regulation of expression of mouse tetrameric alpha-2-macroglobulin results in very constant levels, similar to alpha-2-macroglobulin in humans; ii) single chain murinoglobulin, not alpha-2-macroglobulin, is subject to regulation of expression during pregnancy, around birth, and in adolescence; iii) an important role seems implicated for the alpha-2-macroglobulin receptor in placental lipid metabolism, probably making it the most important lipoprotein receptor to supply the fetus; iv) the massive increase in apolipoprotein E synthesis in uterus and placenta accentuate the changed lipid metabolism during pregnancy to an apolipoprotein E-based uptake by the alpha-2-macroglobulin receptor/lipoprotein receptor related protein; v) the increased expression of lipoprotein lipase underlines its role in the generation of free fatty acids in uterus and placenta as another mechanism of supply, next to receptor mediated endocytosis of lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595098

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Do long-term HDL-C declines associated with a first birth vary by apo E phenotype? The Coronary Artery Risk Development in Young Adults (CARDIA) study.

Authors:  Erica P Gunderson; Rachel A Whitmer; Cora E Lewis; Charles P Quesenberry; Delia Smith West; Stephen Sidney
Journal:  J Womens Health (Larchmt)       Date:  2005-12       Impact factor: 2.681

2.  Uptake of dietary retinoids at the maternal-fetal barrier: in vivo evidence for the role of lipoprotein lipase and alternative pathways.

Authors:  Lesley Wassef; Loredana Quadro
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

3.  Maternal apo E genotype is a modifier of the Smith-Lemli-Opitz syndrome.

Authors:  M Witsch-Baumgartner; M Gruber; H G Kraft; M Rossi; P Clayton; M Giros; D Haas; R I Kelley; M Krajewska-Walasek; G Utermann
Journal:  J Med Genet       Date:  2004-08       Impact factor: 6.318

4.  Hepcidin bound to α2-macroglobulin reduces ferroportin-1 expression and enhances its activity at reducing serum iron levels.

Authors:  Michael Li-Hsuan Huang; Christopher J D Austin; Marie-Agnès Sari; Yohan Suryo Rahmanto; Prem Ponka; Daniel Vyoral; Des R Richardson
Journal:  J Biol Chem       Date:  2013-07-11       Impact factor: 5.157

5.  Low-Density Lipoprotein Receptor Contributes to β-Carotene Uptake in the Maternal Liver.

Authors:  Varsha Shete; Brianna K Costabile; Youn-Kyung Kim; Loredana Quadro
Journal:  Nutrients       Date:  2016-11-29       Impact factor: 5.717

6.  Dietary Phospholipid-Bound Conjugated Linoleic Acid and Docosahexaenoic Acid Incorporation Into Fetal Liver and Brain Modulates Fatty Acid and N-Acylethanolamine Profiles.

Authors:  Elisabetta Murru; Gianfranca Carta; Claudia Manca; Asgeir Saebo; Michele Santoni; Rafaela Mostallino; Marco Pistis; Sebastiano Banni
Journal:  Front Nutr       Date:  2022-03-10

7.  Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndrome.

Authors:  Marie L Lindegaard; Christopher A Wassif; Boris Vaisman; Marcelo Amar; Elizabeth V Wasmuth; Robert Shamburek; Lars B Nielsen; Alan T Remaley; Forbes D Porter
Journal:  Hum Mol Genet       Date:  2008-09-05       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.